|
Timothy G. Whitten named president, CEO of biopharm company Transave Inc.
(Science Letter Via Thomson Dialog NewsEdge)
Transave Inc., a biopharmaceutical company developing inhaled liposomal formulated drugs for treating lung disease, announced the appointment of Timothy G. Whitten as president and chief executive officer.
Whitten succeeds Frank Pilkiewicz, founder of Transave, who will continue to support the company in a senior consulting role.
Donald J. Hayden, executive chairman of Transave, said the Whitten's leadership would be invaluable as the phase 2 SLIT programs for treating P. aeruginosa infections in cystic fibrosis and lung cancer continue to advance to late stages.
Whitten joins Transave from Pharmacyclics where he was senior vice president of commercial operations and development since 2001. Prior to Pharmacyclics, he was vice president, global marketing, oncology, at BMS. During his 16 years in marketing, sales and strategic planning at BMS, Whitten led the successful U.S. launch and marketing of Taxol (paclitaxel) injection, an oncology product that eventually reached $1 billion in annual sales.
Whitten earned his master's degree in business administration from Colgate Darden Graduate School of Business Administration at University of Virginia and received his pharmacy degree from West Virginia University.
This article was prepared by Science Letter editors from staff and other reports. Copyright 2006, Science Letter via NewsRx.com.
[ Back Hosted VoIP Global Community's Homepage ]
|